Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma

Published:2012-07 Issue:1 Volume:57 Page:101-107
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Personeni Nicola,Bozzarelli Silvia,Pressiani Tiziana,Rimassa Lorenza,Tronconi Maria Chiara,Sclafani Francesco,Carnaghi Carlo,Pedicini Vittorio,Giordano Laura,Santoro Armando

Publisher

Elsevier BV

Subject

Hepatology

Reference27 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

3. Measuring the clinical response: what does it mean?;Therasse;Eur J Cancer,2002

4. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma;Abou-Alfa;J Clin Oncol,2006

5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with DEB-TACE;Journal of Hepatocellular Carcinoma;2024-07

2. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study;Frontiers in Immunology;2024-02-16

3. Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial‐level analysis;Cancer;2024-01-17

4. The use of tumor markers in prognosis of cancer and strategies to prevent cancer predisposition and progress;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

5. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy;Hepatology;2023-09-11